CN105726523B - It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application - Google Patents
It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application Download PDFInfo
- Publication number
- CN105726523B CN105726523B CN201610215529.4A CN201610215529A CN105726523B CN 105726523 B CN105726523 B CN 105726523B CN 201610215529 A CN201610215529 A CN 201610215529A CN 105726523 B CN105726523 B CN 105726523B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- present
- acariasis
- active ingredient
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Abstract
The present invention provides a kind of pharmaceutical composition for being used to treat animal acariasis, and the active ingredient of described pharmaceutical composition consists of the following composition：Eugenol, thymol and carvacrol.The present invention also provides preparation method and its application in the medicine for preparing treatment animal acariasis of aforementioned pharmaceutical compositions.The present invention pharmaceutical composition have the advantages that in terms of animal acariasis is treated safely, effectively, toxicity is low, pollution-free；Residual is few in use for the pharmaceutical composition of the present invention, and preparation technology is simple, and cost is low, is conveniently prepared into various preparations；It is easy to use, directly apply and put affected part on the skin；Cure rate is up to 85%, efficient up to more than 95%.
Description
Technical field
The invention belongs to technical field of pharmaceuticals, and in particular to a kind of pharmaceutical composition and its system for being used to treat animal acariasis
Preparation Method and application.
Background technology
Animal acariasis is a kind of animal chronic epizoonosis caused by acarid parasitic animal body surface, and its cause of disease is scabies
Mite, itch mite, autumn Mo, winter and the early spring are taken place mostly in, be directly or indirectly infected by contact with healthy animal by infected animal, extensively
It is general to betide the animals such as ox, sheep, horse, dog, rabbit, chicken, it can also infect and give people, be infected in pastoral area, farming and pastoral area and scale livestock farming
Rate and the incidence of disease are higher.Animal occur the disease be mainly shown as appetite reduce or it is useless absolutely, become thin, hair comes off, serious shadow
The production performance and economic value of sound of movement thing are serious to restrict animal husbandry sound development and economic benefit.It is presently used for treating animal
The medicine of acariasis is mainly chemical synthesis and antibiotics, and such as ivermectin, mite are net, and such medicine is dynamic in effective preventing and treating
While thing acariasis, due to medicament residue, the problems such as causing public health, food security and ecological environment again.
The content of the invention
In order to solve problems of the prior art, the invention provides a kind of medicine group for being used to treat animal acariasis
Compound, the medicine have therapeutic effect to acariasis, have that desinsection is antipruritic, promotes damaged skin to recover, and medicament residue is few, and poison is secondary to be made
With it is small the advantages of.The present invention also provides its preparation method and application.
First purpose of the present invention is to provide a kind of pharmaceutical composition for being used to treat animal acariasis, the drug regimen
The active ingredient of thing consists of the following composition：Eugenol, thymol and carvacrol.
Preferably, percent by volume of the active ingredient in pharmaceutical composition is 1%.
Preferably, the volume ratio of the eugenol, thymol, carvacrol is 1:4:1.
Preferably, described pharmaceutical composition is made up of each component of volumes below percentage：Active ingredient 1%, propane diols
25-30%, glycerol formal 5-10%, dimethyl sulfoxide 5-10%, ethanol 5-10%, azone 0.5-1%, water surplus.
Second object of the present invention is to provide the preparation method of aforementioned pharmaceutical compositions, molten after active ingredient is mixed
In the ethanol of formula ratio, propane diols, dimethyl sulfoxide, glycerol formal, the azone of formula ratio are then added, is well mixed, most
Add the water of formula ratio slowly afterwards, constant volume, grinding stirring while adding, be allowed to uniform, produce.
Third object of the present invention is to provide aforementioned pharmaceutical compositions answering in the medicine for preparing treatment animal acariasis
With.
Fourth object of the present invention is to provide a kind of medicine, and the active ingredient of the medicine is described in claim 1
Pharmaceutical composition.
Preferably, the formulation of the medicine is emulsion.
In the pharmaceutical composition of the present invention, three kinds of being used in combination for compound in terms of mite killing there is Synergistic to make
With can avoid potential drug resistance caused by the use of single compound, can effectively kill to chrysanthemum esters or Yi Wei
The acarid of the Drug-resistants such as rhzomorph, the loss brought by acarid is reduced, promote the recovery of impaired fur, reduce fur damage.Two
The dissolving of the addition promotion Chinese medicine ethanol extract of first sulfoxide, glycerol formal and ethanol and transdermal effect, glycerine and azone
Using promoting absorption of the animal to medicine and transdermal.
The pharmaceutical composition of the present invention in terms of animal acariasis treat with safely, effectively, toxicity it is low, pollution-free etc. excellent
Point；Residual is few in use for the pharmaceutical composition of the present invention, and preparation technology is simple, and cost is low, is conveniently prepared into various preparations；Make
With conveniently, directly apply and put affected part on the skin；Cure rate is up to 85%, efficient up to more than 95%.
Embodiment
Following embodiment facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments
Method, it is conventional method unless otherwise specified.Test material used, is city unless otherwise specified in following embodiments
Sell.
The formula of the pharmaceutical composition for treating animal acariasis of the present invention is as follows：
Eugenol, thymol, carvacrol are 1 according to volume ratio:4:1 ratio is mixed into 1ml, propane diols 25-30ml, sweet
Oily formal 5-10ml, dimethyl sulfoxide 5-10ml, ethanol 5-10ml, azone 0.5-1ml, adds water to 100ml.
The preparation method of the pharmaceutical composition for treating animal acariasis of the present invention is：
Three kinds of compounds that example by volume is measured are dissolved in the ethanol of formula ratio, add formula ratio propane diols,
Dimethyl sulfoxide, glycerol formal, azone, it is well mixed, then blows slowly and add the water of formula ratio, constant volume, grinding stirring while adding,
It is allowed to uniform, produces emulsion.
Embodiment 1
Preparing for the pharmaceutical composition of the present invention is as follows：
167 μ L eugenols, 666 μ L thymols, 167 μ L carvacrols are mixed, are dissolved in 8ml ethanol, the third the two of addition
Alcohol 28ml, glycerol formal 8ml, dimethyl sulfoxide 8ml, azone 0.8ml, it is well mixed, then adds water slowly to 100ml, it is fixed
Hold, grinding stirring while adding, be allowed to uniform, produce emulsion.
Embodiment 2
Preparing for the pharmaceutical composition of the present invention is as follows：
167 μ L eugenols, 666 μ L thymols, 167 μ L carvacrols are mixed, are dissolved in 10ml ethanol, the third the two of addition
Alcohol 25ml, glycerol formal 10ml, dimethyl sulfoxide 5ml, azone 0.5ml, it is well mixed, then adds water slowly to 100ml, it is fixed
Hold, grinding stirring while adding, be allowed to uniform, produce emulsion.
Embodiment 3
Preparing for the pharmaceutical composition of the present invention is as follows：
1.67mL eugenols, 6.66mL thymols, 1.67mL carvacrols are mixed, are dissolved in 50ml ethanol, addition
Propane diols 300ml, glycerol formal 50ml, dimethyl sulfoxide 100ml, azone 10ml, it is well mixed, then adds water extremely slowly
1000ml, constant volume, grinding stirring while adding, it is allowed to uniform, produces emulsion.
The effect experiment of the pharmaceutical composition of the present invention of embodiment 4
1. experimental animal
The rabbit of natural infection acarid, the kg of body weight 1.8~2.2, Lanzhou Institute of Biological Products's Experimental Animal Center carry
For.
2. test drug
A, the emulsion pharmaceutical composition prepared for previous embodiment extraction；
B, volume ratio is that 1% eugenol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
C, volume ratio is that 1% thymol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
D, volume ratio is that 1% carvacrol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
E, the eugenol, thymol, carvacrol that volume ratio is 1%, mixed emulsion, the volume ratio of three is 1:1:1, it is transdermal
Agent and other excipient are consistent with formula ratio in the present invention.
3. test method
30 rabbits for infecting acarid are randomly divided into five groups, first group every two days to smearing this at rabbit external auditory meatus crust
The medicine 2ml prepared is invented, is smeared altogether three times；Second group every two days to smearing 1% eugenol emulsion at rabbit external auditory meatus crust
2ml, smear altogether three times；3rd group every two days to 1% thymol emulsion is smeared at rabbit external auditory meatus crust, smear altogether secondary；4th
Group, to 1% carvacrol emulsion 2ml of smearing at rabbit external auditory meatus crust, was smeared three times altogether every two days；5th group every two days to outside rabbit
1% eugenol, thymol, carvacrol mixed emulsion are smeared at duct crust（The volume ratio of three is 1:1:1）, smear altogether secondary.
Above-mentioned two groups are observed 10 days altogether.
4. curative effect determinate standard
Recovery from illness：Rabbit external auditory meatus has no crust, scrapes a small amount of skin and observes under the microscope and has no polypide.
Take a turn for the better：Rabbit external auditory meatus crust significantly reduces, and scraping crust observes the reduction of polypide quantity under the microscope.
It is invalid：Rabbit external auditory meatus crust has no reduction, observes polypide quantity under the microscope and has no reduction.
5. result
6 are smeared using the pharmaceutical composition of the present invention, cure rate is respectively 100%.The cure rate of experimental group 2,3,4 and 5
Only 50%, 66.67%, 66.67% and 83.33%, it is below embodiment group.Drug therapy rabbit of the invention as can be seen from the results
Acariasis has good effect.Refer to table 1.
Effect of the different pharmaceutical of table 1 to rabbit acariasis
The effect experiment of the Chinese medicine composition of the present invention of embodiment 5
1. experimental animal
Lanzhou pet clinic dog 30.
2. medicine
Test drug：
A, the emulsion pharmaceutical composition prepared for previous embodiment extraction；
B, volume ratio is that 1% eugenol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
C, volume ratio is that 1% thymol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
D, volume ratio is that 1% carvacrol emulsion, transdermal agent and other excipient are consistent with formula ratio in the present invention；
E, the eugenol, thymol, carvacrol that volume ratio is 1%, mixed emulsion, the volume ratio of three is 1:1:1, it is transdermal
Agent and other excipient are consistent with formula ratio in the present invention.
3. test method
30 dogs of natural infection acarid are randomly divided into five groups, first group uniformly applied every two days to the affected part for suffering from mite dog
The medicine 5ml of the embodiment of the present invention is smeared, is smeared altogether three times；Second group was uniformly smeared 1% cloves every two days to the affected part for suffering from mite dog
Phenol emulsion 5ml, smear altogether three times；3rd group was uniformly smeared 1% thymol emulsion 5ml every two days to the affected part for suffering from mite dog, was applied altogether
Smear secondary；4th group was uniformly smeared 1% carvacrol emulsion 5ml every two days to the affected part for suffering from mite dog, was smeared altogether three times；5th group
Every two days 1% eugenol, thymol, carvacrol mixed emulsion were uniformly smeared to the affected part for suffering from mite dog（The volume ratio of three is 1:
1:1）5ml, smear altogether secondary.Above-mentioned two groups are observed 10 days altogether.
4. curative effect determinate standard
Recovery from illness：The affected part for suffering from acariasis dog has no that crust or crust are reduced, and scrapes a small amount of skin and observes under the microscope and has no
Polypide, and fur recovers good；
Take a turn for the better：The affected part crust for suffering from acariasis dog is reduced, and scraping a small amount of skin, to observe polypide under the microscope less, and fur
Recover；
It is invalid：The affected part crust for suffering from acariasis dog has no reduction, and micro- Microscopic observation polypide has no reduction, or even increases, and
Fur does not improve.
5. result
6 are smeared using the pharmaceutical composition of the present invention, cure rate is respectively 100%.The cure rate of experimental group 2,3,4 and 5
Only 66.67%, 83.33%, 66.67% and 83.33%, it is below embodiment group.Medicine of the invention is controlled as can be seen from the results
Treating dog acariasis has good effect.Refer to table 2.
Effect of the different pharmaceutical of table 2 to dog acariasis
Finally it should be noted that：The preferred embodiments of the present invention are the foregoing is only, are not intended to limit the invention,
Although the present invention is described in detail with reference to the foregoing embodiments, for those skilled in the art, it still may be used
To be modified to the technical scheme described in foregoing embodiments, or equivalent substitution is carried out to which part technical characteristic.
Within the spirit and principles of the invention, any modification, equivalent substitution and improvements made etc., it should be included in the present invention's
Within protection domain.
Claims (5)
- A kind of 1. pharmaceutical composition for being used to treat animal acariasis, it is characterised in that：The active ingredient of described pharmaceutical composition by Following component forms：Eugenol, thymol and carvacrol；The eugenol, thymol, the volume ratio of carvacrol are 1:4:1.
- 2. pharmaceutical composition according to claim 1, it is characterised in that：Body of the active ingredient in pharmaceutical composition Product percentage is 1%.
- 3. pharmaceutical composition according to claim 1 or 2, it is characterised in that：Described pharmaceutical composition is by volumes below hundred Divide each component composition of ratio：Active ingredient 1%, propane diols 25-30%, glycerol formal 5-10%, dimethyl sulfoxide 5-10%, ethanol 5- 10%th, azone 0.5-1%, water surplus.
- 4. the preparation method of any described pharmaceutical compositions of claim 1-3, it is characterised in that：After active ingredient is mixed, It is dissolved in the ethanol of formula ratio, then adds propane diols, dimethyl sulfoxide, glycerol formal, the azone of formula ratio, is well mixed, The water of formula ratio is finally added slowly, constant volume, grinding stirring while adding, is allowed to uniform, is produced.
- 5. application of any described pharmaceutical compositions of claim 1-3 in the medicine for preparing treatment animal acariasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610215529.4A CN105726523B (en) | 2016-04-08 | 2016-04-08 | It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610215529.4A CN105726523B (en) | 2016-04-08 | 2016-04-08 | It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105726523A CN105726523A (en) | 2016-07-06 |
| CN105726523B true CN105726523B (en) | 2018-03-09 |
Family
ID=56253059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610215529.4A Active CN105726523B (en) | 2016-04-08 | 2016-04-08 | It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105726523B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110012903A (en) * | 2019-03-28 | 2019-07-16 | 佛山市正典生物技术有限公司 | Can the new merit chigger disease of prevention and control plants essential oil microcapsule formulation and preparation method thereof |
| CN109999014A (en) * | 2019-03-28 | 2019-07-12 | 佛山市正典生物技术有限公司 | It is a kind of can the new merit chigger disease of prevention and control plants essential oil and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1224444A (en) * | 1996-07-03 | 1999-07-28 | 尤尼利弗公司 | Antimicrobial cleaning compositions contg. aromatic alcohols or phenols |
| CN1809368A (en) * | 2003-04-24 | 2006-07-26 | 范德比尔特大学 | Compositions and methods for controlling insects |
| CN103037881A (en) * | 2010-04-16 | 2013-04-10 | 泽达国际公司 | Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
-
2016
- 2016-04-08 CN CN201610215529.4A patent/CN105726523B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1224444A (en) * | 1996-07-03 | 1999-07-28 | 尤尼利弗公司 | Antimicrobial cleaning compositions contg. aromatic alcohols or phenols |
| CN1809368A (en) * | 2003-04-24 | 2006-07-26 | 范德比尔特大学 | Compositions and methods for controlling insects |
| CN103037881A (en) * | 2010-04-16 | 2013-04-10 | 泽达国际公司 | Novel formulations of active ingredient(s) of plant origin or synthetic analogues thereof or of extract(s) of plant origin containing same, and of lecithin |
Non-Patent Citations (5)
| Title |
|---|
| 《天然植物提取物和抗生素改善肉鸡代谢性能的比较研究》;魏建东 等;《第六次全国饲料营养学术研讨会论文集》;20101001;第41页 * |
| 《天然植物药物防治家畜螨虫病的研究及其应用现状》;严作廷 等;《中国畜牧兽医》;20111231;第38卷(第11期);第165-168页 * |
| 11种丙基酚类物质对朱砂叶螨的杀螨活性;张静 等;《中国农学报》;20101231;第26卷(第17期);第285-288页 * |
| 丁香杀螨活性成分的追踪分离纯化与结构鉴定;阮娜 等;《中国农学通报》;20050930;第21卷(第9期);全文 * |
| 植物源杀螨活性物质复配增效研究;梁伟博;《中国优秀硕士学位论文全文数据库 农业科技辑》;20120515(第5期);第30页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105726523A (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mikaeili et al. | Antifungal activities of Astragalus verus Olivier. against Trichophyton verrucosum on in vitro and in vivo guinea pig model of dermatophytosis | |
| Shanks et al. | The efficacy of selamectin in the treatment of naturally acquired infestations of Sarcoptes scabiei on dogs | |
| CN1173820A (en) | Pharmaceutical composition for the treatment of herpes | |
| KR101281470B1 (en) | Compositions for skin external comprising castor oil extracted hexane, undecylenic acid, propyl alcohol, propylene glycol and water for prevention or treatment of tinea pedis | |
| Maggiore et al. | Chemoprophylactic and therapeutic efficacy of thymol in murine cystic echinococcosis | |
| CN105726523B (en) | It is a kind of to be used to treat pharmaceutical composition of animal acariasis and its preparation method and application | |
| Ribeiro et al. | Effects of Spigelia anthelmia decoction on sheep gastrointestinal nematodes | |
| Börkü et al. | Ivermectin is an effective treatment for bovine cutaneous papillomatosis | |
| Sullivan et al. | Toxicology of podophyllin. | |
| JP2019178170A (en) | Use of patchouli extract in preparation of compositions with anti-microorganism effect | |
| Bansal et al. | Comparative study of antibacterial activity of two different earthworm species, Perionyx excavatus and Pheretima posthuma against pathogenic bacteria | |
| Soltani et al. | Shirazi thyme (Zataria multiflora) essential oil suppresses the expression of PavA and Hly genes in Lactococcus garvieae, the causative agent of lactococcosis in farmed fish | |
| CN103230583A (en) | Animal norfloxacin nicotinate compound injection for treating intestinal diseases and preparation method of injection | |
| US1870107A (en) | Medicated ointment composition | |
| RU2702124C2 (en) | Method for prevention and therapy of otoacariasis of carnivores and rabbit psoroptic mange | |
| Ma et al. | Efficacy of different dosages of ivermectin injectable against the Hypoderma spp. in yaks | |
| Papadopoulos et al. | Administration of moxidectin for treatment of sarcoptic mange in a flock of sheep | |
| Clark Jr et al. | Effect of Actinospectacin (Trobicin) in Experimental Syphilis in the Rabbit—II: II. IN SUBCLINICAL INCUBATING SYPHILIS | |
| Han et al. | Formulating a therapeutic cream for burn injury using cyanobacterial extracts and gold nanoparticles | |
| JP2006501223A (en) | How to treat a fungal infection | |
| CA3103390A1 (en) | Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid | |
| Ibrahim | Veterinary traditional practices in Nigeria | |
| Pawłowski et al. | Effect of mebendazole on hydatid cysts in pigs | |
| CN114652708B (en) | Composition for treating deep tissue pain | |
| Kotb et al. | Epidemiological studies of Egyptian buffaloes mange with special reference to efficacy of different therapeutic trials for treatment of mange |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |